RAD51 and ovarian cancer: For instance, in the context of homologous recombination deficiency (HRD), RAD51 foci can guide the use of PARP inhibitors (PARPis) in patients without mutations in HR-related genes suffering from breast and ovarian cancer [62,63,64].